SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Biocon trades higher on the BSE

11 Nov 2022 Evaluate

Biocon is currently trading at Rs. 284.10, up by 8.55 points or 3.10% from its previous closing of Rs. 275.55 on the BSE.

The scrip opened at Rs. 276.05 and has touched a high and low of Rs. 284.45 and Rs. 276.05 respectively. So far 51264 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 410.50 on 08-Feb-2022 and a 52 week low of Rs. 258.30 on 17-Oct-2022.

Last one week high and low of the scrip stood at Rs. 284.45 and Rs. 272.20 respectively. The current market cap of the company is Rs. 33682.83 crore.

The promoters holding in the company stood at 60.64%, while Institutions and Non-Institutions held 23.55% and 15.81% respectively.

Biocon’s subsidiary -- Biocon Biologics has been featured on the prestigious Asia IP ELITE list for 2022 by lntellectual Asset Management (lAM) for its world class Intellectual Property (IP) management and IP value creation in the Asia-Pacific region.

Biocon was the first and only pharmaceutical company from India to be featured on the ASIA IP ELITE list in 2016. Biocon Biologics debuted on the list in 2019. This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list, which recognizes companies across the Asia-Pacific region that demonstrate a sustained commitment to building best-in-class in-house lP functions and continuous excellence in lP value creation.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

380.55 -2.05 (-0.54%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×